Drug Pricing Day At The US Supreme Court

Case before high court involving Medicare payment to hospitals for discounted outpatient drugs does not directly involve manufacturers. But the scope of the ruling could have a profound effect on how much leeway the government has to address drug pricing using administrative tools.

US Supreme court building with 1st statue on left
• Source: Brenda Sandburg

The US Supreme Court is poised to make a decision that could fundamentally rewrite a long-established precedent with potentially sweeping societal consequences.

Roe v. Wade? No. We’re talking about 340B.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access